Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes

• Status: Unknown status
• Trial end date: 2018-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The intestinal microflora imbalance has been associated with obesity and type 2 diabetes. The researchers' study aimed to investigate the effect of saxagliptin on gut microbiota in patients with newly diagnosed type 2 diabetes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Chao Yang Hospital
• Treatments: Saxagliptin

Criteria

Inclusion Criteria:

• Females or males, and aged 20 to 65 years.

• Newly diagnosed type 2 diabetes

• HbA1C ≥7% and HbA1C <9%

Exclusion Criteria:

• Hepatic insufficiency (ALT or AST> 1.5*ULN)

• Renal insufficiency [Creatinine clearance rate (Ccr)]<60ml/min estimated from MDRD equation)

• Coronary artery disease

• Thyroid disease

• Infectious disease

• Systemic inflammatory disease

• Cancer

• Subjects who were taking agents known to influence gut microbiota

• Pregnant or lactating woman

• Other conditions at investigator's discretion